Iovance hits two-year high after raising annual revenue forecast
29/09/2026 15:11
BUZZ-Iovance hits two-year high after raising annual revenue forecast ** Shares of Iovance Biotherapeutics IOVA.O rise 27.5% to $14, their highest level in more than two years
** Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln
** "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint," CEO says
** 8 of 10 brokerages rate the stock "buy" or higher and two "hold"; median PT is $11 — data compiled by LSEG
** Including session's move, stock has jumped more than five times in value YTD
(Reporting by Anand Gopal in Bengaluru)
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies